MRWM
DNA icon

ML&R Wealth Management’s Ginkgo Bioworks DNA Stock Holding History

ML&R Wealth Management’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-375
Closed -$47K – 65
2022
Q3 		$47K Buy
+375
New +$44.7K 0.02% 65

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

ML&R Wealth Management's DNA Position: Q4 2022 in Review

ML&R Wealth Management sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 375 shares — an estimated $47K sold.

ML&R Wealth Management first reported a position in DNA in Q3 2022 and held it in 1 quarter. The position peaked at $47K in Q3 2022. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

  • ML&R Wealth Management reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
  • ML&R Wealth Management sold 375 Ginkgo Bioworks shares in Q4 2022, an estimated $47K.
  • ML&R Wealth Management first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 1 quarter.
  • ML&R Wealth Management's Ginkgo Bioworks position peaked at $47K in Q3 2022.
  • 320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on ML&R Wealth Management's 13F filing for Q4 2022, filed 6 Feb 2023.